Letko Brosseau & Associates Holding in Hudbay Minerals (HBM) Has Increased by $4.57 Million as Stock Declined; As Abiomed (ABMD) Market Value Rose, Bluestein R H & Company Raised Its Stake by $3.49 Million

January 20, 2018 - By Peter Erickson

Letko Brosseau & Associates Inc increased its stake in Hudbay Minerals Inc (HBM) by 2.38% based on its latest 2017Q3 regulatory filing with the SEC. Letko Brosseau & Associates Inc bought 652,300 shares as the company’s stock declined 33.74% while stock markets rallied. The institutional investor held 28.02 million shares of the precious metals company at the end of 2017Q3, valued at $207.21 million, up from 27.36M at the end of the previous reported quarter. Letko Brosseau & Associates Inc who had been investing in Hudbay Minerals Inc for a number of months, seems to be bullish on the $2.38B market cap company. The stock increased 1.63% or $0.15 during the last trading session, reaching $9.35. About 2.00 million shares traded or 160.92% up from the average. Hudbay Minerals Inc. (NYSE:HBM) has risen 39.53% since January 20, 2017 and is uptrending. It has outperformed by 22.83% the S&P500.

Bluestein R H & Company increased its stake in Abiomed Inc (ABMD) by 728.07% based on its latest 2017Q3 regulatory filing with the SEC. Bluestein R H & Company bought 20,750 shares as the company’s stock rose 15.32% with the market. The hedge fund held 23,600 shares of the health care company at the end of 2017Q3, valued at $3.98M, up from 2,850 at the end of the previous reported quarter. Bluestein R H & Company who had been investing in Abiomed Inc for a number of months, seems to be bullish on the $10.09 billion market cap company. The stock increased 1.06% or $2.4 during the last trading session, reaching $228.29. About 179,201 shares traded. ABIOMED, Inc. (NASDAQ:ABMD) has risen 40.97% since January 20, 2017 and is uptrending. It has outperformed by 24.27% the S&P500.

Among 12 analysts covering Abiomed (NASDAQ:ABMD), 10 have Buy rating, 0 Sell and 2 Hold. Therefore 83% are positive. Abiomed had 26 analyst reports since August 4, 2015 according to SRatingsIntel. Piper Jaffray maintained the shares of ABMD in report on Thursday, January 4 with “Buy” rating. William Blair reinitiated the stock with “Buy” rating in Thursday, June 8 report. Jefferies maintained it with “Buy” rating and $208.0 target in Thursday, November 2 report. The rating was maintained by Piper Jaffray with “Hold” on Wednesday, August 5. The rating was maintained by Jefferies on Thursday, June 29 with “Buy”. Guggenheim initiated the stock with “Buy” rating in Wednesday, December 7 report. The rating was downgraded by BTIG Research to “Neutral” on Monday, October 16. Jefferies maintained ABIOMED, Inc. (NASDAQ:ABMD) rating on Thursday, December 21. Jefferies has “Buy” rating and $220.0 target. Jefferies maintained ABIOMED, Inc. (NASDAQ:ABMD) rating on Thursday, September 21. Jefferies has “Buy” rating and $175.0 target. The stock of ABIOMED, Inc. (NASDAQ:ABMD) has “Buy” rating given on Tuesday, August 9 by Jefferies.

Since July 31, 2017, it had 0 buys, and 5 selling transactions for $9.51 million activity. THOMAS PAUL had sold 10,000 shares worth $1.55 million. Greenfield Andrew J had sold 11,282 shares worth $1.91 million. 16,500 ABIOMED, Inc. (NASDAQ:ABMD) shares with value of $2.44M were sold by Weber David M.

Bluestein R H & Company, which manages about $2.94 billion and $1.82 billion US Long portfolio, decreased its stake in Exxon Mobil Corp (NYSE:XOM) by 295,840 shares to 18,854 shares, valued at $1.55 million in 2017Q3, according to the filing. It also reduced its holding in Ibm Corp (NYSE:IBM) by 82,647 shares in the quarter, leaving it with 7,647 shares, and cut its stake in Ecolab Inc (NYSE:ECL).

Investors sentiment decreased to 1.3 in Q3 2017. Its down 0.13, from 1.43 in 2017Q2. It dropped, as 27 investors sold ABMD shares while 89 reduced holdings. 55 funds opened positions while 96 raised stakes. 38.51 million shares or 1.21% less from 38.99 million shares in 2017Q2 were reported. 3,820 are owned by Oakbrook Investments Ltd. Guggenheim Cap has invested 0.07% in ABIOMED, Inc. (NASDAQ:ABMD). Clinton Group Incorporated has 6,688 shares for 0.12% of their portfolio. Great West Life Assurance Co Can stated it has 0.01% in ABIOMED, Inc. (NASDAQ:ABMD). Castleark Limited Co reported 339,961 shares or 1.8% of all its holdings. Nicholas Investment LP holds 71,114 shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 1,511 shares in its portfolio. Alliancebernstein Lp holds 0.01% or 58,816 shares in its portfolio. Morgan Stanley reported 186,519 shares stake. State Street Corp reported 1.10M shares stake. Messner And Smith Theme Value Investment Ltd Ca stated it has 10,648 shares or 2.8% of all its holdings. 12,719 are owned by Advisory Research. Janney Montgomery Scott Limited Liability Co reported 2,903 shares. Bluestein R H And holds 23,600 shares. Loomis Sayles And Lp holds 0.01% in ABIOMED, Inc. (NASDAQ:ABMD) or 28,594 shares.

Among 5 analysts covering Hudbay Minerals Inc (NYSE:HBM), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Hudbay Minerals Inc had 14 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Thursday, August 6 by Canaccord Genuity. The stock of Hudbay Minerals Inc. (NYSE:HBM) has “Outperform” rating given on Thursday, September 29 by BMO Capital Markets. Barclays Capital downgraded the shares of HBM in report on Thursday, January 14 to “Underweight” rating. Credit Suisse maintained the stock with “Neutral” rating in Wednesday, April 19 report. Raymond James maintained Hudbay Minerals Inc. (NYSE:HBM) rating on Thursday, September 3. Raymond James has “Outperform” rating and $10 target. The rating was upgraded by RBC Capital Markets to “Outperform” on Monday, May 16. The stock of Hudbay Minerals Inc. (NYSE:HBM) earned “Market Perform” rating by BMO Capital Markets on Monday, October 2. The rating was downgraded by BMO Capital Markets to “Market Perform” on Tuesday, August 2. Credit Suisse maintained the stock with “Neutral” rating in Monday, September 11 report.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>